January 29, 2015 4:35 AM ET

Biotechnology

Company Overview of Oncos Therapeutics Ltd.

Company Overview

Oncos Therapeutics Ltd., a biotech company, develops cancer therapies based on oncolytic viruses. It designs and develops CGTG-102, an oncolytic adenovirus for the systemic stimulation of anti-tumor immune response, as well as to destroy metastases. The company was founded in 2007 and is based in Helsinki, Finland.

Tukholmankatu 8 A

Helsinki,  00290

Finland

Founded in 2007

Phone:

358 4005 69628

Key Executives for Oncos Therapeutics Ltd.

Chief Executive Officer and President
Co-Founder and Chief Operating Officer
Co-Founder and Chief Scientific Officer
Head of Clinical Science
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Oncos Therapeutics Ltd. Key Developments

Oncos Therapeutics Ltd. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 09:10 AM

Oncos Therapeutics Ltd. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 09:10 AM. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland.

Oncos Therapeutics Ltd. Presents at BIO-Europe 2014, Nov-05-2014 11:45 AM

Oncos Therapeutics Ltd. Presents at BIO-Europe 2014, Nov-05-2014 11:45 AM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

Oncos Therapeutics Ltd. Appoints Dr. Magnus Jaderberg as Chief Medical Officer

Oncos Therapeutics Ltd. announced that it has appointed Dr. Magnus Jaderberg, M.D, Ph.D, as Chief Medical Officer (CMO). Dr. Jaderberg is a pharmaceutical physician with more than 25 years' experience in various R&D functions, including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management. His therapeutic area expertise includes immunology, oncology and infectious diseases. Dr. Jaderberg has experience of all phases of clinical research, including clinical pharmacology, dose finding, registration, post launch product differentiation and surveillance. His immunotherapy expertise includes Yervoy (ipilimumab), Enbrel (etanercept), Torisel (temsirolimus), Orencia (abatacept), Rapamune (sirolimus) and Nulojix (belatacept). Prior to joining Oncos Therapeutics, Dr. Jaderberg held senior position roles at national, European and global level at GlaxoSmithKline, Pharmacia, Wyeth and Bristol Myers Squibb (BMS). His most recent position was as Chief Medical Officer, at BMS Europe. Dr. Jaderberg joined Oncos Therapeutics on June 1, 2014.

Similar Private Companies By Industry

Company Name Region
Next Biomed Technologies Oy Europe
Labsystems, CLIDS Automation, Konelab Europe
Diabor Oy Europe
Nanobac Oy Europe
Mobidiag Oy Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oncos Therapeutics Ltd., please visit www.oncos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.